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Brain-derived neurotrophic factor (BDNF) regulates the survival and growth of neurons, and inﬂuences synaptic efﬁciency and
plasticity. The human BDNF gene consists of 11 exons, and distinct BDNF transcripts are produced through the use of alternative
promoters and splicing events. The majority of the BDNF transcripts can be detected not only in the brain but also in the blood
cells, although no study has yet investigated the differential expression of BDNF transcripts at the peripheral level. This review
provides a description of the human BDNF gene structure as well as a summary of clinical and preclinical evidence supporting
the role of BDNF in the pathogenesis of psychiatric disorders. We will discuss several mechanisms as possibly underlying BDNF
modulation, including epigenetic mechanisms. We will also discuss the potential use of peripheral BDNF as a biomarker for
psychiatric disorders, focusing on the factors that can inﬂuence BDNF gene expression and protein levels. Within this context, we
have also characterized, for we believe the ﬁrst time, the expression of BDNF transcripts in the blood, with the aim to provide novel
insights into the molecular mechanisms and signaling that may regulate peripheral BDNF gene expression levels.
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BDNF AND THE VULNERABILITY TO PSYCHIATRIC DISORDERS
The neurotrophin brain-derived neurotrophic factor (BDNF) is one
of the most studied and characterized neurotrophin in the central
nervous system, and it has received remarkable attention because
of its importance in the development and maintenance of normal
brain function. It has been established that BDNF mediates
survival and differentiation of neurons by binding and activating
the tropomycin receptor kinase B (TrkB), a member of the larger
family of Trk receptors, localized both on the pre-synaptic and
post-synaptic membranes. The binding of BDNF to TrkB leads to
the dimerization and autophosphorylation of tyrosine residues in
the intracellular domain of the receptor and subsequent activation
of cytoplasmic signaling pathways including mitogen-activated
protein kinase, phospholipase C-γ and phosphatidylinositol-3
kinase.1 In addition to neurotrophic effects, BDNF–TrkB signaling
is involved in transcription, translation and trafﬁcking of proteins
during various phases of synaptic development and has been
implicated in several forms of neuroplasticity in different brain
areas. This is especially important, as growing evidence suggests a
role for BDNF in the pathophysiology of brain-associated illnesses,
including psychiatric disorders.2 Indeed, changes in BDNF expres-
sion have been extensively investigated in major depression,
schizophrenia (SZ), bipolar and anxiety disorders, and a plethora
of data demonstrate altered BDNF expression and impaired BDNF
function.3–7 BDNF may also represent a shared risk factor for the
vulnerability of these pathologies, by acting on biological
mechanisms such as neuroplasticity, inﬂammation or hypothala-
mic–pituitary–adrenal axis functionality that are altered in all these
psychiatric disorders.
BDNF and major depression
Reduced BDNF gene expression and protein levels have been
reported in depressed patients, both in post-mortem brain
tissues8–10 and in peripheral blood samples.3,11–14 Importantly,
the investigation of animal models of depression has provided
strong support to these clinical ﬁndings. Indeed, a variety of stress
paradigms in rodents that are able to induce a depressive-like
behavior, such as social defeat, maternal deprivation or prenatal
stress exposure, are associated with a reduction of BDNF mRNA
levels in different brain regions, including the hippocampus and
prefrontal cortex.15–17 Conversely, antidepressant treatments are
able to upregulate BDNF expression in animal models15,18,19 and
also to normalize decreased BDNF blood levels in depressed
subjects.11,14
Emerging data suggest that electroconvulsive treatment in
humans and in animal models may reduce depressive symptoms
by increasing the expression of BDNF. In the systematic review
and meta-analysis of preclinical and clinical data, Polyakova et al.20
tested the association between ECT (electroconvulsive stimulation
in animals) and changes in BDNF concentrations and their effects
on behavior. The authors found that in rodents electroconvulsive
stimulation increased BDNF mRNA and protein concentration in
the brain, with the largest effect size in the dental gyrus. The
increase in BDNF was positively correlated with the number of
treatments and negatively correlated with the time between the
last ECT and BDNF measurement. Moreover, BDNF concentration
did not increase in the course of treatment both in rodent and
human serum samples, yet the levels were increased in human
plasma. The authors concluded that electroconvulsive stimulation
in rodents and ECT in humans can increase BDNF mRNA and
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protein levels, although this effect is not consistently associated
with changes in behavior.
Consistent ﬁndings in clinical samples indicated the presence of
low serum BDNF levels in depressed patients as compared with
healthy subjects, suggesting that decreased peripheral levels of
this gene could represent a ‘state’ characteristic of depression. This
has been supported by several studies,21,22 including our study.13
Bus et al.21 performed a longitudinal study comparing serum
BDNF levels at baseline and after 2 years in a large cohort of
patients with persistent (n= 310), remitted (n= 420) or incident
depression (n= 153), as compared with non-depressed controls
(n= 868). They found a more profound decrease in serum BDNF
levels in patients with persistent and remitted depression than in
controls, whereas the incident depression group did not differ
signiﬁcantly from the non-depressed controls. On these bases, the
authors suggested that the presence of reduced BDNF levels is a
consequence of repeated episodes of depression rather than
being the direct cause of depression development. Moreover,
BDNF levels have been found even more reduced time after the
onset of the illness, possibly reﬂecting the chronicity of the
disorder.
In another interesting study, Molendijk et al.22 analyzed serum
BDNF levels in 962 depressed patients, 700 fully remitted subjects
(46 months) and 382 healthy controls in order to identify
whether (i) abnormalities in BDNF persisted beyond the clinical
state of depression; (ii) BDNF levels were related to the clinical
features of depression; (iii) distinct antidepressants equally
affected BDNF levels. The authors found low serum BDNF levels
in antidepressant-free depressed patients compared with healthy
controls. Moreover, data showed that serum BDNF levels were
lower in depressed patients who were not on antidepressant
medication compared with antidepressant-free subjects who were
in full remission and that BDNF levels of this latter group were
comparable to those of controls.
These data suggest that low protein levels of BDNF in the blood
can be considered as a state characteristic for depression, whose
levels normalize during pharmacological treatment also in relation
to an amelioration of clinical symptoms.
BDNF and SZ
The involvement of BDNF in SZ appears to be more complex.
While it was originally found that BDNF expression is increased in
the brain of patients affected by SZ, as compared with
controls,23,24 a large number of studies have shown that the
expression of BDNF, and of its high-afﬁnity receptor TrkB, is
signiﬁcantly downregulated in schizophrenic subjects.25–27 Several
studies have also reported alterations in BDNF gene expression
and protein levels in the blood of patients affected by SZ,
although the results are quite heterogeneous.28,29 Such hetero-
geneity can be due, at least in part, to the chronicity of the illness
and also to the effects of antipsychotic therapies. Indeed, most of
the data on BDNF in depression come from drug-free depressed
patients and, thus, on patients at their ﬁrst episode who have not
started the pharmacological therapies yet. This is less frequent in
SZ, in which BDNF levels have been primarily measured in patients
with a long disease history, who have been treated with
antipsychotic drugs for a long period of time, and thus in which
the BDNF levels are the results of the chronicity of illness and of
the long-term duration of pharmacological treatment. However, a
recent meta-analysis has clearly shown that subgroup analyses
performed in drug-naive and medicated patients with SZ reveal an
association between reduced BDNF gene expression and protein
levels and SZ, whereas the treatment with antipsychotics does not
exert any signiﬁcant effects on BDNF levels.30,31
BDNF and bipolar disorder
Several studies on peripheral BDNF have been also conducted in
bipolar disorder (BD), however, leading to discrepant results. Most
of these studies have proposed a role for peripheral BDNF as a
state marker also for BD, reporting decreased levels in both mania
and depressive phases, returning to normal in euthymic state.
Thus, it has been suggested that peripheral BDNF could have a
role as a biomarker associated with a diagnosis of BD, in particular
reﬂecting neuroprogressive changes in BD as a stage biomarker.
Related to this, a recent meta-analysis conducted in 52 different
studies by Fernandes et al.32 aimed to verify the properties of
peripheral BDNF serum and plasma levels as a biomarker
associated with disease activity in BD. In particular, the authors
examined the association between BDNF protein levels with the
duration of illness, in order to determine whether peripheral BDNF
levels could represent a stage biomarker of illness. To assess
whether BDNF levels could change during pharmacological
treatment of an acute mood episode, the authors performed a
series of meta-analyses of all cross-sectional studies comparing
peripheral BDNF levels in BD versus healthy subjects. The same
meta-analyses were also conducted, comparing studies before
and after prescription of medication, to explore the relations with
manic and depressive symptoms and response to treatment. The
results indicated that BDNF protein levels were moderately
decreased during the mania phase and largely decreased during
the depressive phase. There were no alterations in peripheral
BDNF levels in euthymia or in mixed states and no association
between BDNF levels and duration of illness.
Several lines of evidence have also suggested that glucocorti-
coids, oxidative stress markers, inﬂammatory cytokines and
neurotrophins may have important roles in BD.33,34 Kauer-
Sant’Anna33 found that BDNF levels were decreased in the late,
but not in the early stage of BD when compared with controls and
appeared to be related to the illness duration. On the other hand,
tumor necrosis factor-alpha and interleukin (IL)-6 protein levels
were increased in both early and late stages of BD, whereas the
anti-inﬂammatory IL-10 was increased in the early stage of BD, but
not at later stages. These data indicated that BD patients may be
in a sort of pro-inﬂammatory state, which worsen during the later
stages of illness, and also suggested that both BDNF and cytokines
may have a key role in the pathophysiology of BD.
In another study, Kose Cinar et al.34 investigated the peripheral
blood BDNF levels of adult male, of drug-free BD patients during
manic and remission periods and of matched controls. They
showed that BDNF levels, as well as those of molecules involved in
BDNF processing (tissue-plasminogen activator), were reduced
during manic episodes, as compared with controls, whereas an
increased BDNF expression was found in remission, as compared
with mania.
BDNF and anxiety disorder
Regarding anxiety disorder, Molendijk et al.35 tested possible
changes in serum BDNF levels also in patients with social anxiety
disorder, panic disorder, generalized anxiety disorder (GAD),
agoraphobia and depressive disorders (that is, major depressive
disorder, minor depressive disorder and dysthymia) as compared
with healthy controls. They also examined the associations with
gender and with other clinical features in these patients. The
results showed no differences between patients and controls in
serum BDNF levels. Additional analyses on gender differences
revealed that female patients had lower serum BDNF levels as
compared with female controls as well as with male patients.
Moreover, BDNF levels in male patients were slightly higher as
compared with male controls, whereas BDNF levels among female
and male controls were similar. The authors also found that the
difference between female and male patients could not be
attributed to the presence of a speciﬁc subtype of anxiety as
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serum BDNF levels were similar across the subtypes, and thus
peripheral BDNF measurements did not have the speciﬁcity to
categorize anxiety disorders. Similarly, Carlino et al. 36 analyzed
serum BDNF levels in adult subjects with different anxiety disorder
subtypes such as social and speciﬁc phobias, GAD and panic
disorder in order to test whether serum BDNF levels could be a
potential biomarker for different subtypes of anxiety disorders. No
signiﬁcant correlation between serum BDNF levels and anxiety
disorders was found as a whole or as a single diagnostic category.
Moreover, no correlation between BDNF levels and severity of
anxiety symptoms was found. However, when patients were
stratiﬁed for both gender and disorder subtype, the authors found
a signiﬁcant decrease in serum BDNF levels, but only in GAD
female patients. In another study, Uguz et al.37 investigated serum
BDNF levels in the cord blood of newborn infants of mothers
with or without GAD during pregnancy. They reported that
newborns of healthy mothers had twofold higher BDNF levels
compared with those of mothers with GAD, suggesting that
GAD may alter neurotrophin levels, thus leading to impaired
neurodevelopment.
As it has been suggested that the presence of low levels of
BDNF could contribute also to the pathogenesis of obsessive-
compulsive disorder also,38 Simsek et al.39 analyzed serum BDNF,
and also cortisol and adrenocorticotropic hormone levels, in
children and adolescents with obsessive-compulsive disorder prior
to treatment, as compared to healthy controls. Serum BDNF,
cortisol and adrenocorticotropic hormone levels were signiﬁcantly
higher in obsessive-compulsive disorder patients than in controls,
suggesting that BDNF levels may increase during the early phase
of the disease and that this increase may represent an adaptive
response to preserve neuronal function in these patients.
THE HUMAN BDNF GENE: STRUCTURE AND TRANSCRIPT
VARIANTS
The human BDNF gene is located on chromosome 11, region p13–
14 and it spans ~ 70 kb. The gene has a complex structure as it
consists of 11 exons (I–IX, plus Vh and VIIIh) in the 5′ end and of
nine functional promoters that are used in tissue and brain
regions speciﬁcally, namely exon I, II (with the transcripts IIa, IIb
and IIc), III, IV, V (with the transcripts Va, Vb, Vc and V–VIII–VIIIh), VI
(with the transcripts VIb, VIb–IXabd and VIb–IXbd), VII (with
transcripts VIIa and VIIb) and IX (with transcripts IXabd and IXabcd;
Figure 1).40 Although the BDNF gene comprises nine exons, the
coding sequence resides in exon 9, with eight upstream exons
that encode promoters regulating regional and cell-type-speciﬁc
expression.41 Among these, exon IV has been the most extensively
characterized, as this exon, containing promoter elements,
regulates activity-dependent BDNF expression.
Each 5′ exon can generate, through alternative splicing, a
speciﬁc transcript or isoform that are all characterized by the
presence of a common coding region at the 3′ end. This 3′ coding
region, located within exon IX, contains the common sequence
that encodes for the pro-BDNF protein. Accordingly, through the
use of alternative promoters and splicing mechanisms, different
BDNF transcripts can be generated, with all of them encoding for
the same pro-BDNF protein product.
Indeed, BDNF is initially synthesized in the endoplasmic
reticulum as a precursor protein (pre-pro-BDNF; ~ 27 kDa);42 the
signal peptide is then cleaved to produce pro-BDNF, the precursor
form of the neurotrophin consisting of a pro-domain of 129 amino
acids and a mature domain of 118 amino acids,2 which is then
transported into the Golgi complex where it is sorted into either
the constitutive or the regulated secretory pathways. Vesicular
Figure 1. Human BDNF gene structure. In the ﬁgure the structure of the human BDNF gene is shown; the gene contains 11 exons (I–IX, plus Vh
and VIIIh), which combine to many different transcripts. Coding DNA sequence (CDS) is in exon IX. Alternative splice-donor sites and CpG
islands are also reported. BDNF, brain-derived neurotrophic factor.
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pro-BDNF is either proteolytically cleaved intracellularly to
generate mature BDNF (mBDNF) or it is secreted as pro-BDNF
and then cleaved at the extracellular level to generate mBDNF.
Vesicular pro-BDNF can be converted intracellularly into mBDNF
by endoproteases, such as furin, or within secretory granules by
pro-protein convertases. Alternatively, pro-BDNF can be cleaved
extracellularly by other factors such as plasmin and matrix
metalloproteinases. Vesicular secretion can involve both pro-
BDNF and mBDNF, with the amount of secreted mBDNF
depending on the type and activity of the convertases.43
The efﬁciency of cleavage, and hence the ratio of pro-BDNF to
mBDNF, is different at distinct developmental stages and during
postnatal life; speciﬁcally, in the neonatal and adolescent stages,
both pro-BDNF and mBDNF are detectable, whereas in adulthood
mBDNF predominates.2 The precursor form or proneurotrophin,
including pro-BDNF, activates the p75 receptor, rather than TrkB
that is activated by mBDNF. The p75 receptor is a member of the
tumor necrosis factor family of receptors that encode a
cytoplasmic death domain and can initiate apoptosis following
ligand binding.44
A pro-BDNF knock-in mouse was generated to examine the
effects of pro-BDNF under the control of its endogenous promoter
and other regulatory elements.45 In this in vivo model, pro-BDNF
expression negatively regulates hippocampal dendritic complexity
and spine density. This ﬁnding suggests that pro-BDNF acts in vivo
as a biologically active factor that regulates hippocampal
structure, synaptic transmission and synaptic plasticity—effects
that are distinctive from the mBDNF. These results, coupled with
the higher levels of expression of pro-BDNF in the developing
postnatal brain, suggest that this ligand may be a key regulator in
shaping neural circuitry and synaptic plasticity in adolescence—
effects that may be maintained also through adulthood.45
Another level of complexity in the BDNF structure is because of
the presence of two alternative polyadenylated transcription stop
sites located within exon IX, that generate two distinct popula-
tions of mRNA with either short (~0.35 kb) or long (~2.85 kb) 3′
untranslated regions (3′ UTRs).2 The diversity of these two clusters
of transcripts is associated with a different neuronal distribution.
Indeed, the short 3′ UTR BDNF mRNA variant is restricted to the
cell body in hippocampal neurons, whereas the long 3′ UTR
mRNAs are also observed in dendrites,46 indicating a speciﬁc
dendritic transport system for the long 3′ UTR BDNF mRNA and
local dendritic translation.
BDNF transcripts IV and IX as the most abundant in human blood
samples
BDNF is not only expressed in the brain, but can also be detected
in peripheral blood cells besides other tissues.47 In the blood,
especially in the context of psychiatric disorders, where blood has
been suggested to be an alternative and useful peripheral tissue
to assess biomarkers of illness, BDNF gene expression studies offer
the opportunity to investigate not only the levels of total BDNF
but also the modulation of different transcripts. The analyses of
the BDNF transcripts may provide novel insights into the
mechanisms regulating BDNF expression and may reveal more
speciﬁc alterations related to a speciﬁc psychiatric condition.
Indeed, although a reduction of total BDNF mRNA is shared by
several psychiatric disorders, including depression and SZ,13,26,30
the modulation of speciﬁc BDNF transcripts may be disease-
speciﬁc or, more importantly, may represent a better predictor in
term of treatment response. However, up to now, no data
are available on the expression of the different BDNF transcripts in
the human blood as well as on BDNF transcript alterations in the
contest of psychiatric conditions.
BDNF transcript expression in human peripheral blood and
hippocampus. We decided to characterize the expression of BDNF
transcripts in peripheral blood cells as compared with brain samples.
To this purpose, we have investigated, using real-time PCR, the
mRNA levels of the main BDNF isoforms (transcripts I, IV, Va, Vb, Vh,
V–VIII–VIIIh, VIb, VIb–IXabd, VIb–IXbd, VIIb, IXabd and IXabcd) in
human blood cells as well as in human hippocampus. RNA from
human hippocampus was obtained from Clontech (Diatech Lab
Line, Milan, Italy), whereas human blood samples were collected in
PaxGene tubes from four control volunteers who signed an
informed consent approved by our Local Ethical Committee. RNA
from peripheral blood cells was isolated by using the PAXgene
miRNA Kit (Qiagen, Milan, Italy) and a pool of RNA samples was
made for qualitative analyses of BDNF transcript expression.
Diluted RNA samples were then run using Biorad qPCR Mix (Bio-
Rad) on a 384-well Real-Time PCR System (Bio-Rad). As shown in
Figure 2, our results indicate that exons IV and IX (namely
transcripts IV, IXabd and IXabcd) are expressed at the highest
expression levels in both tissues, as indicated by low Ct values.
Conversely, the other transcripts, namely Va, Vb, V–VIII–VIIIh, VIb–
IXabd and VIIb, are expressed at low levels in peripheral blood, as
suggested by higher Ct values (440 cycles of PCR), as compared
with brain samples, where their expression is higher (all the Ct
values are o38 cycles of PCR).
To the best of our knowledge, these data provide the ﬁrst
evidence that BDNF exons IV and IX may directly contribute to the
modulation of total BDNF expression at the peripheral level. These
transcripts could contribute to BDNF alterations that are reported
in several psychiatric conditions and could also be modulated by
successful pharmacological treatments.11,13,14,31 The high expres-
sion of BDNF exon IV is particularly intriguing, as its promoter
region is well investigated in term of epigenetic regulation, which
Figure 2. Expression analysis of BDNF splicing variants in human hippocampus and peripheral blood. The graph shows the Ct values obtained
with real-time PCR for the total BDNF mRNA and for the different BDNF splicing variants, as measured in human blood cells (blue bars) or in
the human hippocampus (red bars). BDNF, brain-derived neurotrophic factor.
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may sustain long-lasting changes in its expression (see the below
paragraph for details on BDNF DNA methylation).
EPIGENETIC REGULATION OF BDNF: DNA METHYLATION AND
MICRORNA
DNA methylation
The exact mechanisms that may lead to BDNF alterations in
psychiatric disorders are still largely unknown. Epigenetic changes
at the BDNF gene locus may provide a link between genes and
environment and may also explain the long-lasting nature of the
changes in BDNF expression and function. Epigenetics refers to
alterations in gene expression and in a speciﬁc phenotype without
involving changes within the DNA sequence. Among the
epigenetic mechanisms, DNA methylation probably represents
the process that has been investigated more in detail. In
mammals, DNA methylation occurs largely in association with
CpG dinucleotides, also called CpG islands, where methyl groups
are added to cytosine residues.48,49 As CpG islands tend to cluster
within or close to promoter regions, methylation may represent
one of the mechanisms regulating the transcription of selective
BDNF promoters under different conditions. BDNF promoter IV
represents the best investigated promoter in the contest of DNA
methylation changes associated with alterations in BDNF
expression.50
Up to now, limited knowledge is available on methylation levels
within BDNF exon IV in the context of psychiatric conditions and
most of the available data have been obtained in brain samples.
For example, when compared with controls, a signiﬁcant increase
in DNA methylation at BDNF promoter IV was found in the
Wernicke area from suicide subjects and, interestingly, this higher
methylation pattern correlated with lower mRNA levels for BDNF
transcript IV.51 An increase in DNA methylation levels of this BDNF
promoter region was reported in association with lower BDNF
protein levels in the prefrontal cortex of elderly people.52
Furthermore, higher DNA methylation levels were also found in
the prefrontal cortex of valine/valine homozygous subjects, as
compared with metionine (Met) carriers, suggesting an association
between BDNF genotype and DNA methylation.53 The notion that
epigenetic changes are associated with variations in DNA
sequence may underlie, at least in part, the inconsistencies of
genetic-association studies in psychiatric disorders. Indeed,
polymorphisms can exert an effect on gene function via
epigenetic processes, suggesting a common pathway beyond
genetic and environmental effects as well as a potential
mechanism for gene–environment interaction. This suggests that
an integration between epigenetic and gene association data
could stratify the effect of candidate polymorphisms and
haplotypes on disease vulnerability and may allow the identiﬁca-
tion of vulnerability signatures associated with psychiatric
disorders.
In addition to DNA methylation, histone modiﬁcations, which
inﬂuence the condensation of the DNA around histone proteins
and regulate the accessibility of functional regions to transcrip-
tional regulators, represent an interesting epigenetic mechanism.
There are few studies examining the role of histone modiﬁcations
at the BDNF gene promoter in humans. In post-mortem brain
tissue, the transcriptional upregulation of BDNF, which occurs
from fetal to childhood and/or young adult stages, was shown to
be accompanied by increases in histone methyltransferase H3K4
trimethylation, a mark of active chromatin, at promoters I and IV.54
In depressed patients, two studies suggest that antidepressants
may regulate BDNF expression through alterations in the H3K27
methylation state at promoter IV; for example, H3K27 methylation
was reduced in post-mortem brain tissue of patients who had
used antidepressants, compared with patients without a history of
antidepressant consumption.55 A prospective study conducted in
blood cells of treatment-naive depressed subjects revealed a
decrease in H3K27 methylation in responders, but not in non-
responders after 8 weeks of citalopram treatment.56 Interestingly,
H3K27 methylation was inversely correlated with serum BDNF
levels and treatment efﬁcacy. Only subjects with positive
therapeutic responses to citalopram exhibited higher BDNF and
lower H3K27 methylation, although H3K27 methylation did not
differ between future responders and non-responders before the
treatment period.56
All these studies suggest that DNA methylation at the BDNF
promoter might predict a possible antidepressant response.
DNA methylation analyses of BDNF exon IV promoter region. Here,
in our review, we have also provided a DNA methylation proﬁle of
the promoter region of exon IV, one of the most expressed exons
in peripheral blood and the most investigated BDNF region in
term of epigenetic regulation. We used a bisulphite pyrosequen-
cing approach, including 23 CpG sites, from nucleotide (nt)
27723095 to nt 27723658 of the BDNF gene, spanning the
transcriptional start site. DNA samples were obtained from the
same control subjects that we used for the expression of BDNF
transcripts, and DNA was isolated by using the Gentra Puregene
Blood kit (Qiagen) according to the manufacturer′s instructions.
Genomic DNA was treated with the EZ DNA Methylation-Gold Kit
(Zymo Research) and the bisulﬁte-treated DNA was PCR-
pyrosequenced using the PSQ HS96 Pyrosequencing System.
The assays were designed to cover the greatest number of CpG
sites possible, taking into account the limitations of the method
(PCR amplicon ⩽ 350 bp, primers that avoided CpGs, target
sequence ⩽40 bp). We then expressed the degree of methylation
as percentage of methylated cytosines (% 5-methyl-cytosine). Our
data indicated that the BDNF exon IV region was methylated at
low levels in blood cells. Indeed, as we can observe in Figure 3, 15
CpG sites had less than 5% 5 mC; ﬁve CpG sites had 5–10% 5 mC;
and only three CpG sites showed more than 10% 5mC.
Interestingly, the three CpG sites with the highest level of
methylation status were those located at greatest distance from
the transcriptional start site.
MicroRNAs targeting BDNF
Another biological mechanism that has emerged as an important
epigenetic process is represented by microRNAs (miRNAs).
MiRNAs are endogenous small non-coding RNAs that regulate
the expression of different genes at the post-transcriptional level,
by promoting the cleavage of target mRNAs or by repressing their
translation. MiRNAs have been shown to regulate a variety of
biological processes, including development, cell proliferation,
fate speciﬁcation, growth control and apoptosis.57,58 A ﬁne
regulation of miRNA expression is required for normal brain
development,59,60 whereas changes in the expression and/or
function of speciﬁc miRNAs have been associated with different
mental diseases, such as SZ,61 major depressive disorder,62,63
BD64,65 and autism spectrum disorder.66 Recent studies have
demonstrated that also BDNF expression and function may be
directly regulated through miRNAs. BDNF is potentially regulated
by several hundreds of miRNAs, primarily via its 3′ UTR region, and
Figure 3. DNA methylation proﬁle of exon IV in control subjects. The
ﬁgure shows the methylation proﬁle of 23 CpG sites within the
promoter region of exon IV. The degree of methylation has been
expressed as percentage of cytosines that were methylated (% 5-
methyl-Cytosine). Fifteen CpG sites had o5% 5 mC, ﬁve CpG sites
from 5 to 10% 5 mC and only three CpG sites 410% 5 mC.
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in Supplementary Tables 1 and 2 we have reported a list of
miRNAs that are predicted or that have been validated (according
to miRWalk Database, http://www.umm.uni-heidelberg.de/apps/
zmf/mirwalk/) to target the human or rodent BDNF gene.
Although several miRNAs are predicted to target BDNF, only few
miRNAs have been investigated experimentally. Recently, using in
silico approaches, such as reporter systems and analysis of
endogenous BDNF, it has been shown that miR-1, miR-10b,
miR-155 and miR-191 directly repress BDNF gene expression by
binding to speciﬁc predicted sites within BDNF 3′ UTR.67
Furthermore, an overexpression of miR-1 and miR-10b suppressed
endogenous BDNF protein levels, whereas the silencing of
endogenous miR-10b increased BDNF mRNA and protein levels.
The suppression of BDNF via miR-10b occurred via targeting both
the long and short 3′ UTRs of BDNF, as mutating the putative
miR-10b-binding site within the long 3′ UTR abolished BDNF
suppression.67 The same study showed that miR-155 and miR-191
speciﬁcally reduced the expression of a luciferase construct
containing the long, but not the short, 3′ UTR of the neurotrophin.
The authors also measured BDNF levels after transfecting neural
cell lines with pre-miRNAs, showing that the majority of BDNF
transcripts containing the short 3′ UTR did not respond to miR-155
or miR-191. Consistently with this notion, the expression of BDNF
mRNA isoforms carrying the long 3′ UTR was reduced following
treatment with miR-155 and miR-191 precursors, although total
BDNF mRNA and BDNF protein levels were unaffected.67
The effect of miR-1 on BDNF expression was also investigated in
a recent study where its overexpression in human primary
glioblastoma (U87) cells caused a decrease in BDNF protein levels,
suggesting a negative effect of this miR-1 on BDNF protein
levels.68 Similarly to miR-1, miR-206 shares the same predicted
binding site within the 3′ UTR of the BDNF mRNA, and different
studies have shown that miR-206 suppresses BDNF expression via
its 3′ UTR region.69–71 For example, Lee et al.70 examined miRNA
expression in transgenic Alzheimer‘s disease mice and human
Alzheimer‘s disease brain samples, showing that miR-206 regu-
lates BDNF transcription and that the antagomir AM206, a speciﬁc
inhibitor of miR-206, enhances BDNF gene expression levels,
synaptogenesis and neurogenesis. However, other studies
reported that BDNF mRNA levels are not regulated by miR-
-206,72,73 although endogenous BDNF expression is reduced after
treating C2C12 myoblasts with miR-206.72
Recently, Imam et al.74 examined the role of miR-204 in
regulating BDNF expression reporting that endogenous BDNF
mRNA and protein levels were reduced after miR-204 over-
expression, whereas an increased neurotrophin expression was
found after inhibition of endogenous miR-204. Furthermore, this
miRNA suppressed luciferase expression via the full-length BDNF
3′ UTR, an effect that was abolished after mutating the predicted
binding site of miR-204. Furthermore, overexpression of another
miRNA, namely miR-210, in HEK-293 cells leads to a down-
regulation of BDNF, whereas an upregulation of the neurotrophin
was observed after transfection of anti-miR-210 oligonucleotide.75
A number of other miRNAs, including miR-15a, miR-22, miR-26a
and miR-26b, miR-30a, miR-124, miR-132, miR-182, miR-195 and
miR-376b-5p, have been shown to regulate BDNF expression. For
example, Mellios et al.54 have found that miR-30a-5p and miR-195
target the 3′ UTR of BDNF demonstrating that miR-30a-5p
overexpression in rat forebrain neurons markedly reduces BDNF
protein. Recently, a marked reduction in BDNF mRNA levels was
found in a mouse paradigm that mimics binge alcohol drinking in
humans, an effect that was associated with an increased
expression of several miRNAs, including miR-30a-5p, in the medial
prefrontal cortex.76 The authors demonstrated that miR-30a-5p
binds the 3′ UTR region of BDNF, and that overexpression of this
miRNA in the medial prefrontal cortex decreased BDNF expres-
sion. Conversely, inhibition of miR-30a-5p, by using a locked
nucleic acid sequence targeting miR-30a-5p, restored BDNF levels
and decreased excessive alcohol intake.76 These studies provide
evidence for a role of miRNA in selectively regulating the
expression of the pool of BDNF transcripts, which undergo
dendritic targeting and may contribute to local, activity-depen-
dent, neurotrophin synthesis.15,77,78
On the basis of the regulation of BDNF by different miRNAs, it
may be inferred that these epigenetic regulators could contribute
to the development of psychiatric disorders in which BDNF is
having a key role. Accordingly, Li et al.79 showed that the
reduction of serum BDNF levels in patients affected by depression
is paralleled by an upregulation of miR-132 and miR-182,
suggesting that miRNA dysregulation may contribute to the
changes of neurotrophin gene expression levels in depressed
subjects. A recent report has shown that miR-16 has an important
role in the negative modulation of hippocampal neurogenesis and
depression-like behaviors.80 Interestingly, an upregulation of
miR-16 and a downregulation of BDNF mRNA expression was
found in the hippocampus of maternally deprived rats character-
ized by depression-like behaviors, suggesting a potential link
between miR-16 and BDNF.81
Furthermore, it has been demonstrated that BDNF Val66Met is
associated with an altered expression of a speciﬁc subsets of
miRNAs and of their downstream targets. Indeed, Hsu et al.82
suggest that Val66Met can affect miRNA levels by modulating the
afﬁnity of the miRNA on the target-binding region on BDNF gene
according to the presence of the Val or Met allele. These results
suggest that BDNF Val66Met may mediate its effects on
psychiatric and cognitive phenotypes in part because of miRNA-
dependent effects on gene expression.
BDNF AS PERIPHERAL BIOMARKER FOR PSYCHIATRIC
DISORDERS
Disease biomarkers can be deﬁned as biological alterations of
speciﬁc molecules that either have diagnostic or predictive value
in relation to an illness, allowing an estimation of a patient’s
responsiveness to a speciﬁc treatment.83,84 Biomarkers can be
potentially found in any biomedical context, helping in the
differential diagnosis of psychiatric disorders, which usually show
an overlapping symptomatology.11 Toward this goal, identiﬁcation
of biological markers could improve and facilitate the classiﬁcation
of disease subtypes, as well as could control the response to
medication, allowing a stratiﬁcation of the patients into more
homogeneous, clinically distinct subpopulations.85
Up to now, genome-wide association studies have not
identiﬁed any signiﬁcant association between common variants
within BDNF gene and psychiatric disorders. This could be
because of the evidence that psychiatric disorders are complex
diseases involving several common variants within different
vulnerability genes, each contributing with a small effect size.
Moreover, these disorders are also characterized by a complex
interplay between genetic and environmental factors. In line with
this, several ﬁndings have now reported an interaction between
the Val66Met SNP with environmental factors, and in particular
childhood adversities, in inﬂuencing the formation of hippo-
campus,86,87 or in leading to an enhanced vulnerability to suicide
88 in depressed patients. In addition, genetic epistasis between
BDNF Val66Met with Serotonin Transporter 1 or Catechol-O-
methyltransferase functional SNPs in moderating depression
vulnerability has been reported in several studies.89–91
On the basis of the association between BDNF and several
psychiatric disorders, particularly depression,11–13,92,93 this neuro-
trophin has been suggested to represent a valuable biomarker for
a speciﬁc psychiatric condition as well as for treatment response.
Unfortunately, cerebrospinal ﬂuid levels of BDNF are already at
the limit of detection in healthy individuals, despite the sensitivity
of analytic methodologies.94 Moreover, the analysis of BDNF in
brain tissues is restricted to autoptic examination, which
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represents a big limitation as studies on post-mortem tissues are
subjected to several artifacts, related to medication, cause of
death, agonal state and post-mortem interval.95,96 Hence, in order
to have the possibility to investigate BDNF in living individuals,
during the last decade a number of studies have investigated the
gene expression and protein levels of the neurotrophin in the
peripheral blood, which may provide signiﬁcant advantages,
being readily available in large quantities with minimally invasive
techniques.11,97
Interestingly, when BDNF was ﬁrst measured in the peripheral
blood of depressed patients and controls, Karege et al. reported
that BDNF serum and plasma levels were reduced in drug-free
depressed patients, as compared with controls.98,99 These data
have been subsequently replicated by different groups, including
our own group,13,100 which consistently demonstrate that plasma
or serum BDNF levels are reduced in depressed patients and may
be normalized following effective antidepressant
treatments.3,11,12,101 Interestingly, in a recent meta-analysis,
Polyakova et al.3 showed a reduction of serum and plasma BDNF
levels not only in depressed patients, but also in bipolar subjects,
as compared with healthy ones. Indeed, alterations of circulating
BDNF levels are not speciﬁc for major depression, as they have
been found also in other psychiatric disorders.30,84 Another recent
meta-analysis has demonstrated that serum BDNF levels are
reduced in chronic schizophrenic patients31,102 as well as in ﬁrst-
episode psychotic subjects.103 These results may not be surprising,
given that stress, which represents a risk factor not only for
depression, but also for SZ and other psychiatric disorders, is able
to reduce BDNF levels.47 Thus, the reduction in peripheral BDNF
may underlie common pathophysiological mechanisms, charac-
terized by reduced neuronal plasticity, which may be shared by
several mental diseases.
Given that brain BDNF crosses the blood–brain barrier,104 it is
reasonable to assume that blood BDNF gene expression and
protein levels resemble those in the brain. This hypothesis has
been upheld by data showing a positive correlation between
serum BDNF and cortical levels of the neurotrophin in rats during
neurodevelopment98 and by a positive association between BDNF
serum content and cortical levels of N-acetyl aspartate, a marker of
neuronal integrity.105 However, the high concentration of BDNF in
the blood may not only originate from the brain, but also from
other peripheral sources. Within blood, BDNF is mainly stored, but
not synthesized, in platelets/thrombocytes.98,99,106,107 This may
explain the ~ 200-fold difference between BDNF levels deter-
mined in serum versus plasma, probably because of the release of
BDNF from platelets into serum during coagulation.99 However,
platelets may serve as storage compartment for BDNF deriving
from different sources, thus representing active factors in the
regulation of BDNF homeostasis.106 Interestingly, a deﬁcit in the
BDNF release from platelets has been shown to occur in
depressed patients.99
BDNF mRNA levels are also signiﬁcantly reduced in the
leukocytes of depressed patients, as compared with controls.100
Our group has conﬁrmed these results, showing decreased BDNF
mRNA expression and reduced serum BDNF levels in the blood of
depressed patients, as compared with a group of controls.14
Importantly, we have also reported that antidepressant treatments
are able to restore BDNF levels to control values and, more
importantly, that a correlation between increased BDNF levels and
symptomatology improvement does occur, suggesting that the
modulation of BDNF may be required in order to achieve a
positive clinical outcome.14 Moreover, we have also found a
correlation between BDNF mRNA levels in leukocytes and BDNF
protein levels in the serum both at baseline and during
antidepressant treatment, suggesting that the changes in BDNF
protein levels found in depressed patients may be, at least in part,
related to the synthesis and secretion of BDNF from white blood
cells rather than from platelets only.99,108
Importantly, BDNF mRNA expression in peripheral blood may
reﬂect more accurately the central mechanism of BDNF physiol-
ogy, as compared with protein levels.47 In support of this
hypothesis, the mRNA proﬁle of peripheral blood cells shows an
overlap with those observed in different brain regions,109–111
suggesting that blood cells may provide valuable information on
the pathogenesis of different brain disorders, including psychiatric
diseases, and may lead to the identiﬁcation of innovative
biomarkers for diagnostic assessment and personalized
treatments.112,113
Although peripheral BDNF gene expression and protein levels
have been often suggested as biomarkers for several psychiatric
disorders and in particular for depression, limitations exist and
should be discussed. Unfortunately, the majority of the published
studies are very heterogeneous, showing a very small effect size.
Moreover, according to many authors, peripheral BDNF alterations
are not speciﬁc enough for a given psychiatric disorder. Future
studies should be designed following a multidisciplinary
approach, thus taking into account BDNF expression and protein
levels with methylation.
In order to examine the potential determinants (sampling
characteristics, sociodemographic variables, lifestyle indicators
and chronic diseases) inﬂuencing serum BDNF levels, Bus
et al.114 conducted a study in a large and well-deﬁned cohort of
people without current psychiatric or neurologic diseases. The
authors identiﬁed eight independent determinants of serum BDNF
levels: (1) time of blood withdrawal, (2) time of storage, (3) food
intake before sampling, (4) urbanicity, (5) age, (6) sex, (7) smoking
status and (8) drinking behavior. According to these ﬁndings, the
authors suggest that future studies on serum BDNF levels in
humans should take into account and correct for all these
variables. Although effect sizes are generally small and clinical
relevance needs to be tested in subsequent clinical samples, the
authors also suggested the importance of excluding smokers,
excessive alcohol drinkers and subjects who did not adhere to the
pretest fasting protocol from clinical studies and to keep storage
time limited.
Another interesting confounder associated with BDNF changes,
shown by Molendijk et al.,115 is the pronounced seasonal variation
in serum BDNF concentrations of both depressed patients and
healthy controls: an increasing BDNF concentration has been
found over the course of the spring and summer, whereas
decreasing BDNF levels have been identiﬁed over the course of
the autumn and winter. As reported also by the authors, these
results provide strong evidence that serum BDNF concentrations
systematically vary over the year and should be taken into account
when designing and interpreting studies on BDNF.
CONCLUSIONS
Several lines of evidence suggest that BDNF may represent a key
factor in the pathogenesis of different psychiatric disorders.
Although the exact mechanisms underlying this relationship
remain to be fully established, epigenetic factors, such as DNA
methylation and miRNAs, may be involved. Moreover, BDNF exons
IV and IX represent the most abundant transcripts in peripheral
blood, suggesting their key role in BDNF regulation at the
peripheral level. On these bases, the analysis of these transcripts
may provide novel insights into the mechanisms contributing to
BDNF modulation under pathologic conditions as well as during
pharmacological treatments.
Importantly, as we have addressed in this review, peripheral
BDNF gene expression and protein levels in serum or plasma have
been consistently found dysregulated in several psychiatric
disorders, including major depressive disorder, SZ, BD and anxiety
disorders. Thus, peripheral BDNF levels cannot be considered as a
biomarker for speciﬁc clinical manifestations and psychiatric
symptoms. BDNF splice variants, in turn, could represent more
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speciﬁc peripheral biomarkers for a differential diagnosis of
psychiatric disorders. Indeed, speciﬁc BDNF isoforms are modu-
lated by speciﬁc factors and are involved in differential pathways;
thus, they could reﬂect alterations in speciﬁc signals and could
represent possible useful biomarkers associated with a differential
diagnosis, but this needs further investigation. However, our main
hypothesis is that the presence of reduced BDNF levels, observed
across several psychiatric disorders, could represent a transdiag-
nostic biomarker, indicator of reduced neural plasticity and ability
in stress-related coping mechanisms, which are features reported
to be altered in all these psychiatric disorders.
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